Immune Regulation in Chronic Aspergillus Infection After COVID-19 Infection
Study Details
Study Description
Brief Summary
This study aims to collect clinical cases and follow-up data from patients with chronic pulmonary aspergillosis, post-COVID-19 aspergillosis, and post-COVID-19 patients without aspergillosis. Using in vitro assays, we will measure the phagocytic function of neutrophils when stimulated by fungal hyphae, their ability to produce neutrophil extracellular traps (NETs), the expression of cell surface molecules at the time of enrollment, changes in cell surface molecule expression after stimulation with fungal hyphae, and the quantification of autoantibodies in the blood. This research will focus on the short-term (within 3 months), medium-term (6-12 months), and long-term (more than 12 months) changes in cell surface molecules and functions following infection.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Aspergillosis Patients with aspergillosis |
Other: This is a blood test without regarding to intervention nor diagnostic tests
This is a blood test without regarding to intervention nor diagnostic tests
|
| COVID Patients with history of COVID infection and without aspergillosis |
Other: This is a blood test without regarding to intervention nor diagnostic tests
This is a blood test without regarding to intervention nor diagnostic tests
|
| Control Patients without history of COVID infection and without aspergillosis |
Other: This is a blood test without regarding to intervention nor diagnostic tests
This is a blood test without regarding to intervention nor diagnostic tests
|
Outcome Measures
Primary Outcome Measures
- Overall survival [6 months intervel]
The study will observed for at least one year for overall survival
Secondary Outcome Measures
- Oppertunistic infection [yearly]
Infection not by aspergillus or COVID
Eligibility Criteria
Criteria
Inclusion Criteria:
- Confirmed cases include patients diagnosed with pulmonary aspergillosis, acute or subacute Aspergillus infections, and aspergillosis in other anatomical sites (such as sinuses, middle ear, liver). Additionally, this study will enroll patients with chronic obstructive pulmonary disease (COPD), asthma, or those undergoing treatment for pulmonary tuberculosis who continue to exhibit worsening pulmonary radiological findings without a clear etiology, necessitating hospitalization or outpatient care for unexplained community-acquired pneumonia. Patients with bronchiectasis, emphysema, pulmonary fibrosis, or other chronic pulmonary conditions who are under continuous follow-up and treatment at our institution will also be included if clinically diagnosed with aspergillosis.
The control group will consist of patients who, based on clinical evidence, have no history of prior exposure to Aspergillus or aspergillosis infection after contracting COVID-19.
Exclusion Criteria:
- Individuals aged below 20, pregnant women, patients with advanced-stage (stage II and above) lung cancer, individuals diagnosed with malignancies, patients with mental health disorders requiring consent from a legal guardian for participation, and those in critical end-stage conditions.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Shiang Fen Huang | Taipei | Taiwan | 112 |
Sponsors and Collaborators
- Taipei Veterans General Hospital, Taiwan
- National Science and Technology Council
Investigators
- Principal Investigator: SF Huang, Taipei Veterans General Hospital, Taipei, Taiwan
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2023-01-002BC